Abatacept
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abatacept and local guidelines before prescribing.
Mechanism
Fusion protein that blocks CD28 co-stimulation of T cells (selective T-cell co-stimulation modulator).
Uses
Rheumatoid arthritis and psoriatic or juvenile idiopathic arthritis after inadequate response to DMARDs.
Dosing
- Treatment: Stop the checkpoint inhibitor; IV methylprednisolone 500–1000 mg daily for 3–5 days, then oral steroid taper; second-line agents (e.g. abatacept, mycophenolate, ruxolitinib) for steroid-refractory disease.
Cardiology: Cardiomyopathies › 3.37 Immune Checkpoint Inhibitor Myocarditis
Side effects
Infections (including respiratory), headache, nausea; rarely serious infection, malignancy, infusion reactions.
Interactions
Avoid with other biologics (TNF inhibitors); live vaccines contraindicated.
Contraindications and cautions
Active serious infection; caution with COPD, recurrent infection, latent TB or hepatitis B
Monitoring
TB and hepatitis B screen before starting; infection symptoms
Pregnancy and breastfeeding
Avoid unless essential; limited data
Renal and hepatic impairment
No dose adjustment
Overdose and reversal
No specific antidote; stop and treat infection
Special advice
Screen for TB and hepatitis B before starting; avoid live vaccines; interrupt in serious infection.
More from the textbook: uses, cautions and other points
- T-cell co-stimulation | Abatacept | RA
Rheumatology Anatomy Physiology Pharmacology - T-cell costimulation | Abatacept | RA | Infections; fewer serious infections than some others
Rheumatology: assessment, investigations and drugs - Anti-TNF, abatacept, tocilizumab or sarilumab, JAK inhibitors - usually with methotrexate.
Rheumatology: Inflammatory arthritis - Clinically suspect arthralgia - joint pain with features suggesting early RA (anti-CCP positive) but no swelling yet; watch; trials of early abatacept and methotrexate are exploring prevention.
Rheumatology: Inflammatory arthritis - Drugs acting on T cells - calcineurin inhibitors (tacrolimus, ciclosporin - block IL-2), corticosteroids, abatacept (blocks co-stimulation), anti-thymocyte globulin.
Clinical Immunology: Immune system basics and immunological investigations - CTLA4 haploinsufficiency and LRBA deficiency - CVID-like antibody deficiency with autoimmunity, enteropathy and lymphocytic infiltration - abatacept (CTLA-4–Ig) is targeted therapy.
Clinical Immunology: Primary immunodeficiency
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Rheumatology: Inflammatory arthritis (3 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (3 mentions)
- Integrated cardiology chapter (1 mention)